Overview

Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost 0.005% to Preservative Free Tafluprost Eye Drops

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Santen Oy
Treatments:
Latanoprost
Ophthalmic Solutions
Criteria
Inclusion Criteria:

- Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the
patient has been using latanoprost 0.005% as his/her prior medication. - Evaluable
patients must have ocular surface related symptoms and/or signs with their prior
medication.